several companies began to offer cheaper tests for the BRCA1 and BRCA2 mutations. Myriad and its partners in the suit says that even though the patents on the natural genes are invalidated, Gene by ...

Together, these studies represent a major step forward in variant classification, providing essential data that helps clinicians better assess cancer risks tied to genetic mutations. Ambry ...

“Such a high rate of a false positives in this particular study was unexpected,” says study coauthor Stephany Tandy-Connor of Ambry Genetics, in a statement. She notes that differences in testing ...